CJC-1295 (No DAC) vs Melanotan 1: Mechanism, Half-Life & Research Use

Direct Comparison: CJC-1295 (No DAC) vs Melanotan 1

CJC-1295 (No DAC) and Melanotan 1 differ fundamentally in target receptors and biological cascades. CJC-1295 (No DAC) is a tetrasubstituted GHRH analog targeting pituitary somatotrophs to elevate growth hormone and downstream IGF-1 levels. Conversely, Melanotan 1 is a synthetic alpha-MSH analog targeting melanocortin receptors (MC1R–MC5R) to modulate melanogenesis and metabolic signaling in preclinical models.

To streamline protocol design and compound selection, the core chemical and biological parameters of both research compounds are summarized in the comparative matrix below:

| Criteria | CJC-1295 (No DAC) | Melanotan 1 (Afamelanotide) | | :--- | :--- | :--- | | **Mechanistic Class** | GHRH Analog / Secretagogue | Alpha-MSH / Melanocortin Agonist | | **Primary Target Receptor** | GHRH Receptor (GHRHR) | Non-selective MC1R, MC3R, MC4R, MC5R | | **Reported Half-Life** | ~30 minutes (In vivo rodent models) | ~30–60 minutes (Plasma clearance) | | **Primary Downstream Markers** | GH, IGF-1, IGFBP-3 | Eumelanin, cAMP accumulation, MC4R signaling | | **Solubility Profile** | Water-soluble, dilute acetic acid | Water-soluble, phosphate-buffered saline | | **Typical Preclinical Models** | Rodent tissue repair, somatotropic axis | Melanocyte culture, photoprotection, metabolic assays | | **Vial Configuration** | 2mg, 5mg lyophilized powder | 10mg lyophilized powder |

Mechanistic Profile of CJC-1295 (No DAC)

CJC-1295 (No DAC), also referred to as Modified GRF 1-29, is a 29-amino-acid synthetic peptide modified with four amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27). These specific substitutions enhance enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV) cleavage while maintaining affinity for the GHRH receptor located on anterior pituitary somatotroph cells.

In laboratory research settings, CJC-1295 (No DAC) is primarily studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. By binding to GHRHR, it triggers adenylate cyclase activation, rising intracellular cyclic adenosine monophosphate (cAMP) levels, and stimulating the pulsatile release of endogenous growth hormone without disrupting natural feedback loops.

Preclinical studies suggest that the absence of the Drug Affinity Complex (DAC) allows CJC-1295 (No DAC) to produce short, physiological bursts of GH release rather than continuous, prolonged elevation. This makes it an essential tool for investigators studying physiological somatotropic dynamics, muscle protein synthesis, cartilage repair, and cellular regeneration in vitro and in animal models.

Mechanistic Profile of Melanotan 1

Melanotan 1 (also known as Afamelanotide or [Nle4, D-Phe7]-alpha-MSH) is a synthetic 13-amino-acid peptide derived from native alpha-melanocyte-stimulating hormone. Structural modification through the substitution of D-phenylalanine at position 7 and norleucine at position 4 yields significantly higher metabolic stability and potency compared to endogenous alpha-MSH.

The primary mechanism of Melanotan 1 involves non-selective activation of the melanocortin receptor family, displaying high binding affinity for MC1R, MC3R, MC4R, and MC5R. Activation of MC1R on epidermal melanocytes triggers G-protein coupled cascades that upregulate microphthalmia-associated transcription factor (MITF) and tyrosinase expression, accelerating eumelanin synthesis.

In preclinical literature, Melanotan 1 is heavily researched for its photoprotective properties, skin pigmentation pathways, and potential role in central melanocortin receptor activity related to energy homeostasis and neuroinflammation. Because it does not interact with the pituitary GHRH receptor, it exerts no direct influence on somatotropic signaling or growth hormone release.

Pharmacokinetics, Stability, and Half-Life Considerations

Understanding pharmacokinetic clearance is vital when designing dosing schedules for animal models or sampling intervals for in vitro assays. Standard native GHRH exhibits an extremely short plasma half-life of less than 12 minutes due to rapid cleavage by DPP-IV. Modifications in CJC-1295 (No DAC) extend its active half-life in rodent models to approximately 30 minutes, preserving a natural, pulsatile secretory pattern.

Melanotan 1 also displays extended stability compared to native alpha-MSH. In vivo plasma clearance studies indicate an elimination half-life ranging from 30 to 60 minutes depending on the animal species and delivery matrix. The modification at D-Phe7 provides resistance against central endopeptidase degradation.

When handling both compounds in the laboratory, thermal and enzymatic degradation must be minimized. Both peptides are provided as lyophilized powders to ensure stability during shipping. Reconstitution using sterile solvents must be executed immediately prior to protocol execution, and aliquot storage at -20°C or -80°C is recommended to prevent hydrolysis.

Preclinical Application & Study Design Selection

Selecting between cjc-1295 (no dac) vs melanotan 1 depends entirely on the biological system under evaluation. Researchers seeking to investigate metabolic rate, somatotroph responsiveness, protein retention, or musculoskeletal recovery will find CJC-1295 (No DAC) structurally suited to their parameters. Its ability to stimulate pulsatile GH release makes it ideal for models investigating IGF-1-mediated cellular repair.

Conversely, projects focused on dermatological research, melanogenesis, UV-radiation defense mechanisms, central melanocortin signaling, or appetite modulation pathways require a melanocortin agonist like Melanotan 1. Because Melanotan 1 bypasses the somatotropic axis, it allows researchers to isolate melanocortin-driven pathways without confounding elevations in systemic growth factors.

For protocols requiring accurate concentration calculations prior to assay setup, researchers can utilize our interactive reconstitution calculator to determine precise solvent volumes and final molar concentrations.

Comparative Analysis of Related Secretagogues and Melanocortins

To broader the context of your experimental design, it is helpful to contrast CJC-1295 (No DAC) and Melanotan 1 with other popular research peptides within their respective functional classes. Within the somatotropic secretagogue category, CJC-1295 (No DAC) is frequently paired with ghrelin mimetics like Ipamorelin to evaluate synergistic GH release, or compared against first-generation analogs like Sermorelin which possess shorter plasma half-lives.

Within the melanocortin peptide family, Melanotan 1 is often compared against Melanotan 2. While Melanotan 1 is a linear peptide with higher selectivity for MC1R photoprotective pathways, Melanotan 2 is a cyclic analog with enhanced blood-brain barrier penetration and broader central nervous system activity. Researchers evaluating complete secretagogue profiles can review our research library hub or explore our complete catalog of all research peptides.

Laboratory Reconstitution, Handling, and Storage Standards

To maintain the structural integrity of both CJC-1295 (No DAC) and Melanotan 1, strict laboratory handling standards must be maintained. Both peptides are sensitive to temperature fluctuations, mechanical shear stress, and exposure to atmospheric oxygen after unsealing.

Lyophilized vials should be stored at -20°C upon receipt for short-term projects or -80°C for long-term storage. Prior to reconstitution, vials should be allowed to acclimate to room temperature to prevent condensation inside the container. Reconstitution should be performed using bacteriostatic water (0.9% benzyl alcohol) or sterile isotonic saline, depending on assay compatibility. Direct high-velocity liquid streams onto the lyophilized cake should be avoided; instead, dilute down the glass vial wall and gently swirl until fully dissolved.

PX1 Research Quality Verification & Sourcing Standards

Reproducibility in preclinical research relies fundamentally on chemical purity and batch-to-batch consistency. PX1 Research manufactures all research compounds inside state-of-the-art, GMP-compliant USA facilities. Every single batch undergoes stringent testing through an independent ISO 17025 accredited laboratory.

Our quality verification protocol includes high-performance liquid chromatography (HPLC) to confirm purity levels exceeding 99%, mass spectrometry (MS) to verify precise molecular weight, and chromogenic LAL assays to ensure strict endotoxin control (<0.05 EU/mg). Laboratory representatives can verify batch compliance by viewing a third-party Certificate of Analysis (COA) or contact our team regarding wholesale and institutional accounts.